// App-Quantinova.ai

TPS180 : UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).

Researchers

Presenter

  • Arun Azad

Principal Investigators

  • Nattakorn Dhiantravan

  • Louise Emmett

  • Anthony M. Joshua

  • Ian Vela

  • David A. Pattison

  • Roslyn J. Francis

  • Scott Williams

  • Shahneen Kaur Sandhu

  • Ian D. Davis

  • Nitika Neha

  • Mathias Bressel

  • Declan G. Murphy

  • Michael S Hofman

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia

  • Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

  • Princess Alexandra Hosp, Murarrie, Australia

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • Sir Charles Gairdner Hospital, Perth, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia

  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia

  • University of Melbourne Peter MacCallum Cancer Center, Melbourne, Australia.

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multiple Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04343885

Sponsors

  • Peter MacCallum Cancer Centre

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved